This inventor holds 2 USPTO granted patents. Top assignee: Aventis Pharma S.a.. Active years: 2004-2006.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2004-2006
Title: Cyrille Leperlier: Innovator in Neuroleptic Treatments
Introduction
Cyrille Leperlier is a notable inventor based in Fontainebleau, France. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of schizophrenia. With a total of 2 patents, his work focuses on innovative combinations of medications that aim to improve patient outcomes.
Latest Patents
Cyrille Leperlier's latest patents include a combination of cyamemazine and an atypical neuroleptic. This invention relates to the use of cyamemazine alongside atypical neuroleptics, such as olanzapine or risperidone, for the treatment of schizophrenia, especially during acute episodes. These advancements highlight his commitment to addressing complex mental health challenges through innovative pharmaceutical solutions.
Career Highlights
Cyrille Leperlier is associated with Aventis Pharma S.A., where he has been instrumental in developing new therapeutic approaches. His work has contributed to the understanding and treatment of schizophrenia, showcasing his expertise in the pharmaceutical industry.
Collaborations
Cyrille collaborates with Michel Dib, a fellow professional in the field. Their partnership emphasizes the importance of teamwork in driving innovation and improving treatment options for patients.
Conclusion
Cyrille Leperlier's contributions to the field of neuroleptic treatments demonstrate his dedication to advancing mental health care. His innovative patents and collaborations reflect a commitment to improving the lives of those affected by schizophrenia.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile